U.S. patent application number 10/676832 was filed with the patent office on 2005-10-06 for method for the improvement of islet signaling in diabetes mellitus and for its prevention.
Invention is credited to Demuth, Hans-Ulrich, Glund, Konrad.
Application Number | 20050222221 10/676832 |
Document ID | / |
Family ID | 22716142 |
Filed Date | 2005-10-06 |
United States Patent
Application |
20050222221 |
Kind Code |
A1 |
Demuth, Hans-Ulrich ; et
al. |
October 6, 2005 |
Method for the improvement of islet signaling in diabetes mellitus
and for its prevention
Abstract
The present invention discloses a method for therapeutically
treating mammals, including but not limited to humans, to increase
the relative insulin producing performance of endogenous pancreatic
.beta.-cells and to cause differentiation of pancreatic epithelial
cells into insulin producing .beta.-cells. Oral administration a DP
IV inhibitor causes the active form of GLP-1 to be preserved longer
under physiological conditions. The extended presence of GLP-1, in
particular in the pancreatic tissue facilitates differentiation and
regeneration of the .beta.-cells already present that are in need
of repair. These repaired insulin producing cells can contribute to
the correction and maintenance of normal physiological glycemic
levels.
Inventors: |
Demuth, Hans-Ulrich; (Halle,
DE) ; Glund, Konrad; (Halle, DE) |
Correspondence
Address: |
OSI PHARMACEUTICALS, INC.
58 SOUTH SERVICE ROAD
MELVILLE
NY
11747
US
|
Family ID: |
22716142 |
Appl. No.: |
10/676832 |
Filed: |
October 1, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10676832 |
Oct 1, 2003 |
|
|
|
10196038 |
Jul 16, 2002 |
|
|
|
10196038 |
Jul 16, 2002 |
|
|
|
09824622 |
Apr 2, 2001 |
|
|
|
6500804 |
|
|
|
|
60194061 |
Mar 31, 2000 |
|
|
|
Current U.S.
Class: |
514/365 ;
514/423 |
Current CPC
Class: |
A61P 3/00 20180101; A61P
37/06 20180101; Y10S 514/866 20130101; A61P 5/50 20180101; A61K
31/00 20130101; A61P 29/00 20180101; A61P 31/18 20180101; A61P
31/00 20180101; A61P 3/10 20180101; A61P 19/02 20180101; A61K 45/06
20130101; A61P 37/00 20180101; A61P 19/00 20180101; A61K 31/426
20130101; A61K 31/40 20130101; A61P 43/00 20180101; A61P 5/00
20180101 |
Class at
Publication: |
514/365 ;
514/423 |
International
Class: |
A61K 031/426; A61K
031/401 |
Claims
What is claimed is:
1. A method for increasing the capacity of insulin providing cells
in an animal comprising administering to said animal a
therapeutically effective dose of at least one DP IV enzyme
activity effector.
2. The method of claim 1 wherein said increasing the capacity of
insulin producing cells comprises causing endogenous insulin
producing cells to become more effective insulin producers.
3. The method of claim 1 wherein said increasing the capacity of
insulin producing cells comprises causing cells present in the
pancreas to differentiate into insulin producing cells.
4. The method of claim 1 wherein said DP IV effector is selected
from the group consisting of N-(N'-substituted
glycyl)-2-cyanopyrrolidines, N-aminoacyl thiazolidines, N-aminoacyl
pyrrolidines: such as L-threo-isoleucyl thiazolidine (P32/98),
L-allo-isoleucyl thiazolidine, L-threo-isoleucyl pyrrolidine, and
L-allo-isoleucyl pyrrolidine and pharmaceutical salts thereof.
5. The method of claim 1 wherein said effector comprises a
substrate capable of binding with said DP IV and which competes
with naturally occurring substrates for DP IV.
6. The method of claim 1 wherein said administration comprises oral
administration.
7. The method of claim 1 wherein said administration comprises iv
or im injection.
8. The method of claim 1 wherein said administration comprises
chronic oral administration.
9. The method of claim 1 wherein said administration comprises
chronic iv or im injection.
10. The method of claim 1 further comprising the administration of
glucose or the intake of food takes place before, during or after
the administration of said DP IV activity effector.
11. The method of claim 8 wherein said administration of said DP IV
activity effector occurs before said administration of glucose, or
intake of food.
Description
CROSS REFERENCES TO RELATED APPLICATIONS
[0001] This application claims priority of the U.S. Provisional
Patent Application Ser. No. 60/194,061 filed Mar. 31, 2000 which is
incorporated by reference in its entirety.
BACKGROUND
[0002] The pancreas comprises two glandular tissues, one, is a
collection of cells that form the exocrine function of the pancreas
where these exocrine cells synthesize and release digestive enzymes
into the intestine; the second tissue comprises the endocrine
function of the pancreas which synthesize and release hormones into
the circulation. Of prime importance in the endocrine function of
the pancreas, are the .beta.-cells. These cells synthesize and
secrete the hormone insulin. The hormone insulin plays a vital role
in maintaining normal physiological glycemic levels. There are
molecules that are effectors of the endocrine cells of the
pancreas. Incretins are an example of such molecules. Incretins
potentiate glucose-induced insulin secretion from the pancreas.
[0003] Incretins such as glucagon-like peptide-1 (7-36) amide
("GLP-1"; Pr the lizard analog Exendin-4) and gastric inhibitory
polypeptide ("GIP") have been demonstrated to be insulinotropic,
i.e., their presence or stabilization can maintain acute glycemic
control by their insulin-secretive effects (Demuth, H. U., et al.,
DE 196 16 486:1-6, 1996; Pauly, R. P. et al., Regul. Pept. 64
(1-3): 148, 1996, the teachings of which are incorporated herein by
reference in their entirety). Additionally, it has been
demonstrated that GLP-1 acts, as an islet growth hormone by
stimulating .beta.-cell proliferation, cell mass increase and by
promoting undifferentiated pancreatic cells in specialized cells of
the islet of Langerhans. Such cells show improved secretion of
insulin and glucagon (Yaekura, K. et al., IN: VIP, PACAP, and
Related Peptides, W. G. Forssmann and S. I. Said (eds.), New York:
New York Academy of Sciences, 1998, p. 445-450; Buteau, J. et al.,
Diabetologia 42(7): 856-864, 1999, the entire teachings of which
are herein incorporated by reference).
[0004] It has been previously proposed to apply exogenous bioactive
GLP-1, or its analogs, to either stimulate islet cell regeneration
in vivo, or to obtain pancreatic cells from diabetes mellitus
patients and to treat such cells ex vivo in tissue culture using
bioactive GLP-1. This ex vivo treatment was considered to
facilitate regeneration and/or differentiation of islet cells which
could then synthesis- and secrete insulin or glucagon (Zhou, J. et
al., Diabetes, 48(12):2358-2366, 1999; Xu, G. et al., Diabetes,
48(12):2270-2276, 1999, the entire teachings of which are herein
incorporated by reference).
[0005] However, such a treatment regime requires the enteral or
parenteral application of bioactive GLP-1 to patients, including
the possibility of surgery. It is one aspect to obviate the need
for surgical treatment, enteral or parenteral applications of
bioactive GLP-1.
SUMMARY
[0006] The present invention relates to a novel method in which the
reduction of activity in the enzyme Dipeptidyl Peptidase (DP IV or
CD 26) or of DP IV-like enzyme activity in the blood of mammals
induced by effectors of the enzyme leads as a causal consequence to
a reduced degradation of the gastrointestinal polypeptide
Glucagon-Like Peptide Amide-1 7-36 (GLP-1.sub.7-36) (or
structurally related functional analogs of this peptide, such as
GLP-1.sub.7-37, or truncated but biologically active fragments of
GLP-1.sub.7-36) by DP IV and DP IV-like enzymes. Such treatment
will result in a reduction or delay in the decrease of the
concentration of functional active GLP-1 (including GLP-1-derived)
circulating peptide hormones or of their analogs.
[0007] As a consequence of the resulting enhanced stability of the
endogenous GLP-1 (including GLP-1-derived) circulating peptides
caused by the inhibition of DP IV activity, GLP-1 activity is
prolonged resulting in functionally active GLP-1 (including
GLP-1-derived) circulating peptide hormones facilitating
growth-hormone-like stimulation of pancreatic cells in such a way
that these cells proliferate to functionally active cells of the
Islets of Langerhans. Additionally, insensitive pancreatic cells or
impaired pancreatic cells may be transformed into functionally
active cells of the islets of Langerhans when exposed to GLP-1.
[0008] It was expected, that the transformation of insensitive
pancreatic cells or impaired pancreatic cells to functionally
active cells of the islets of Langerhans results in an increased
insulin secretion and in an increased insulin level in blood
plasma. Surprisingly, in studies in healthy human volunteers and
obese, diabetic Zucker rats, the insulin level decreased after
treatment with the DP IV inhibitor isoleucyl thiazolidine
hemifumarate (P32/98) (see examples 1 and 2, respectively).
Nevertheless, the resulting regeneration of the islets of
Langerhans does change the efficacy of endogenous insulin and other
islet hormones, such as glucagon, in such a way that stimulation of
carbohydrate metabolism of a treated mammal is effected. As a
result, the blood glucose level drops below the glucose
concentration characteristic for hyperglycemia, as shown in
examples 1 and 2. The mechanism triggering these effects is not
known in detail. However, this resulting regeneration of the islet
cells further effects anomalies of the metabolism including
glucosuria, hyperlipidaemia as well as severe metabolic acidoses
and Diabetes mellitus, by preventing or alleviating these
sequela.
[0009] In contrast to other proposed methods known in the art, such
as pancreatic cell or tissue transplantation or ex-vivo treatment
of pancreatic cells using GLP-1 or exendin-4 followed by
re-implantation of the treated cells, the present invention does
not cause or require complicated and costly surgery, and provides
an orally available therapy. The instant invention represents a
novel approach for lowering the elevated concentration of blood
glucose. It is commercially useful and suitable for use in a
therapeutic regime, especially concerning human disease, many of
which are caused by prolonged elevated or blood glucose levels.
BRIEF DESCRIPTION OF THE FIGURES
[0010] Further understanding of the instant invention may be had by
reference to the figures wherein:
[0011] FIG. 1 is a graphical representation of the time-dependency
of circulating bioactive GLP-1 in humans (n=36) depending on the
orally applied DP IV-inhibitor formulation P32/98;
[0012] FIG. 2 is a graph representing the dependency of the AUC of
circulating bioactive GLP-1 in humans (n=36) on the orally applied
DP IV-inhibitor formulation P32/98;
[0013] FIG. 3 is a graphical representation showing the improvement
of morning blood-glucose (MBG) after subchronic monotherapeutic
application of 8.7 mg/kg/d of P32/98 to obese, diabetic fa/fa
rats;
[0014] FIG. 4a is a graphical representation showing improved
glucose-control due to DP IV-inhibitor treatment after 16-days of
treatment in obese diabetic rats
[0015] FIG. 4b. is a graphical representation showing reduced
insulin-secretion due to DP IV-inhibitor treatment after 16 days of
treatment in obese diabetic rats;
[0016] FIG. 5a is a graphical representation showing the blood
glucose levels as a function of time in the maintenance of improved
glycemia after 21 days of subchronic treatment of obese, diabetic
fa/fa rats by the formulated DP IV-inhibitor p32/98; and
[0017] FIG. 5b is a graphical representation showing the plasma
insulin levels as a function of time in the maintenance of improved
glycemia after 21 days of sub-chronic treatment of obese, diabetic
fa/fa rats by the formulated DP IV-inhibitor p32/98.
DETAILED DESCRIPTION
[0018] The present invention pertains to a novel method for
differentiating and/or reconstituting pancreatic cells. The
resulting regeneration of the islet cells of Langerhans will
positively affect the synthesis and release of endogenous insulin
and other islet hormones, such as glucagon, in such a manner that
the stimulation of carbohydrate metabolism will be effected.
[0019] Glucose-induced insulin secretion is modulated by a number
of hormones and neurotransmitters. Of specific interest are the two
gut hormones, glucagon-like peptide-1 (GLP-1) and gastric
inhibitory peptide (GIP), both of which are insulinotropic agents.
Insulinotropic agents can stimulate, or cause the stimulation of,
the synthesis or expression of the hormone insulin.
[0020] GLP-1 is a potent intestinal insulinotropic agent that
augments insulin secretion and acutely lowers glucose levels,
including levels observed in Type I and Type II diabetes. GLP-1 is
formed by alternative tissue-specific cleavages in the L cells of
the intestine, the .alpha.-cells of the endocrine pancrease, and
neurons in the brain. GIP is synthesized and released from the
duodenum and proximal jejunum postprandially. Its release depends
upon several factors including meal content and pre-existing health
status. It was initially discovered and named for its gastric acid
inhibitory properties. However, as research into this hormone has
progressed, more relevant physiological roles have been elucidated.
Specifically, GIP is an insulinotropic agent with a stimulatory
effect on insulin synthesis and release.
[0021] DP IV is an enzyme that is an exopeptidase which selectively
cleaves peptides after penultimate N-terminal proline and alanine
residues. Endogenous substrates for this enzyme include the
incretins, such as glucose-dependent insulinotropic polypeptides,
like GIP and GLP-1. In the presence of DP IV, these hormones are
enzymatically reduced to inactive forms. The inactive form of GIP
and GLP cannot induce insulin secretion, thus blood glucose levels
are elevated, especially in the hyperglycemic state. Elevated blood
glucose levels have been associated with many different
pathologies, including diabetes mellitus (Type 1 and 2) and the
sequelae accompanying diabetes mellitus.
[0022] It has also been discovered that DP IV plays a role in
T-cell-mediated immune responses, for example, in transplantations.
Inhibition of DP IV has been demonstrated to prolong cardiac
allografts. Additionally, the inhibition of DP IV has contributed
to the suppression of rheumatoid arthritis. DP IV has also been
attributed a role in HIV's penetration into T-cells (T-helper
cells).
[0023] Agents such as N-(N'-substituted
glycyl)-2-cyanopyrrolidines, L-threo-isoleucyl thiazolidine
(P32/98), L-allo-isoleucyl thiazolidine, L-threo-isoleucyl
pyrrolidine, and L-allo-isoleucyl pyrrolidine have been developed
which inhibit the enzymatic activity of DP IV are described in U.S.
Pat. No. 6,001,155, WO 99/61431, WO 99/67278, WO 99/67279, DE 198
34 591, WO 97/40832, DE 196 16 486 C.sub.2, WO 98/19998, WO
00/07617, WO 99/38501, and WO 99/46272, the teachings of which are
herein incorporated by reference in their entirety. The goal of
these agents is to inhibit DP IV, and by doing so, to lower blood
glucose levels thereby effectively treating hyperglycemia and
attendant diseases associated with elevated levels of glucose in
the blood. The inventors hereof have surprisingly discovered that
such agents can be advantageously employed for an entirely
different therapeutic purpose, then previously known by those
skilled in the art.
[0024] Diseases which characteristically demonstrate hyperglycemia
include diseases such as Diabetes mellitus, Type I and II. Diabetes
may generally be characterized as an insufficient hormone output by
the pancreatic .beta.-cells. Normally, these cells synthesize and
secrete the hormone insulin. In Type I diabetes, this insufficiency
is due to destruction of the beta cells by an autoimmune process.
Type II diabetes is primarily due to a combination of beta cell
deficiency and peripheral insulin resistance. In the diabetic
patient, the number of beta cells is reduced so not only is there a
concern regarding the ability of beta cells to synthesize and
release physiological insulin, but there is also a concern
surrounding the critical mass of these insulin producing pancreatic
cells. Loss of beta cells is known to occur with the presence of
diabetes. With the loss of these insulin producing cells, there
exists a strain on the endocrine function of the pancreas to
produce, for example, insulin. With the loss in insulin output,
pathological processes due to hyperglycemia can become
exacerbated.
[0025] GLP-1 acts as an islet growth hormone by stimulating .beta.
cell proliferation, cell mass increase and by promoting
undifferentiated pancreatic cells in specialized cells of the islet
of Langerhans. Such GLP-1 exposed pancreatic cells show improved
secretion of insulin and glucagon (Yaekura, K. et al., IN: VIP,
PACAP, and Related Peptides, W. G. Forssmann and S. I. Said (eds.),
New York: New York Academy of Sciences, 1998, p. 445-450; Buteau,
J. et al., Diabetologia 42(7): 856-864, 1999). The inventors have
discovered that it is desirable to increase GLP-1's half-life to
thereby facilitate reconstitution of the pancreatic beta cells. The
inventors have also discovered a method whereby catabolism of GLP-1
maybe attenuated in order to improve reconstitution of the
pancreatic cells.
[0026] The method of the present invention for treating
hyperglycemia in a mammal, including but not limited to humans,
comprises potentiating GLP-1's presence by inhibiting DP IV, or
related enzyme activities, using an inhibitor of the enzyme. Oral
administration of a DP IV inhibitor may be preferable in most
circumstances. However, other routes of administration are
envisaged in the present invention. By inhibiting the DP IV enzyme
activity, the half-life of the active form of GLP-1 will be
appreciably extended and maintained under physiological conditions.
The extended presence of active GLP-1, in particular in the
pancreatic tissue, will facilitate the differentiation of
pancreatic epithelial cells into pancreatic effector cells, like
insulin producing .beta.-cells. Moreover, prolonging GLP-1's
physiologically active presence in pancreatic tissue will
facilitate the regeneration of those .beta.-cells which are already
present but in need of repair. Surprisingly, this effect is only
observable after repeated dosing (see example 2). Since withdrawel
of the medication resuls in restoration of the prior metabolic
state, subchronic or chronic dosing of the DP IV effector is needed
to maintain the achieved improved glycemia. These repaired insulin
producing cells can then effectively contribute to the correction
and maintenance of normal physiological glycemic levels.
[0027] In the present invention endogenous GLP-1 is synthesized and
released in the normal physiological routes. Ingestion of a meal
can stimulate the release of GLP-1. Alternatively, glucose or its
analog can be given orally in the form of a pharmaceutically
acceptable carrier (for example, a "sugar pill") in order to
stimulate release of endogenous GLP-1. Such glucose may be taken,
before, concurrently or following administration of the DP IV
inhibitors.
[0028] This invention also provides pharmaceutical compositions.
Such compositions comprise a therapeutically (or prophylactically)
effective amount of the inhibitor (and/or a sugar pill to accompany
administration of a DP IV inhibitor), and a pharmaceutically
acceptable carrier or excipient. The carrier and composition are
produced under good laboratory practices conditions and are
sterile. The formulation is ideally selected to suit the mode of
administration, in accordance with conventional practice.
[0029] Suitable pharmaceutically acceptable carriers include but
are not limited to water, salt solutions (for example, NaCl),
alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene
glycols, gelatin, carbohydrates such as lactose, amylose or starch,
magnesium stearate, talc, viscous paraffin, perfume oil, fatty acid
esters, hydroxymethylcellulose, polyvinyl pyrolidone, etc. The
pharmaceutical preparations can be sterilized and if desired mixed
with auxiliary agents, for example, lubricants, preservatives,
stabilizers, wetting agents, emulsifiers, salts for influencing
osmotic pressure, buffers, coloring, flavoring and/or aromatic
substances and the like which do not deleteriously react with the
active compounds, but which improve stability manufacturability
and/or aesthetic appeal.
[0030] The compositions, if desired, can also contain minor amounts
of wetting or emulsifying agents, or pH buffering agents. In
addition, the composition can be a liquid solution, suspension,
emulsion, tablet, pill, capsule, sustained release formulation, or
powder. In addition, the composition can be formulated as a
suppository, with traditional binders and carriers such as
triglycerides. Oral formulations can include standard carriers such
as pharmaceutical grades of mannitol, lactose, starch, magnesium
stearate, polyvinyl pyrollidone, sodium saccharine, cellulose,
magnesium carbonate etc.
[0031] Further, the compositions can be formulated in accordance
with methods that are well known in the art of pharmaceutical
composition adapted for intravenous administration to human beings.
Typically, compositions for intravenous administration are sterile
isotonic aqueous buffered solution. Where necessary, the
composition may also include a solubilizing agent and a local
anesthetic to ease pain at the site of the injection. Generally,
the ingredients are supplied either separately or mixed together in
unit dosage form, for example, as a dry lyophilized powder or water
free concentrate in a hermetically sealed container such as an
ampoule or sachette indicating the quantity of active compound.
Where the composition is to be administered by infusion, it can be
dispensed with an infusion bottle containing sterile pharmaceutical
grade water, saline or dextrose/water. Where the composition is
administered by injection, an ampoule of sterile water for
injection or saline can be provided so that the ingredients may be
mixed just prior to administration.
[0032] Finally, compositions of the invention can be formulated as
neutral or salt forms. Pharmaceutically acceptable salts include
those formed with free amino groups such as those derived from
hydrochloric, phosphoric, acetic, oxalic, tartaric acid, etc., and
those derived from sodium, potassium, ammonium, calcium, ferric
hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol,
histidine, procaine, and other salt forms that are well known in
the art.
[0033] The amount of the invention's composition which will be
effective in the treatment of a particular disorder or condition
will depend on the nature of the disorder or condition, and can be
determined by standard clinical techniques. In addition, in vitro
and/or in vivo assays may optionally be employed to help identify
optimal dosage ranges. The precise dose to be employed in the
formulation will also depend on the route of administration, and
the seriousness of the disease or disorder. The dose should be
decided according to the judgement of the practitioner taking into
consideration each patient's circumstances.
[0034] It will be readily understood by the skilled artisan that
numerous alterations may be made to the examples and instructions
given herein including the generation of different DP IV inhibitors
and alternate therapeutic compositions without departing from
either the spirit or scope of the present invention. The following
examples as described are not intended to be construed as limiting
the scope of the present invention.
EXAMPLES
Example 1
[0035] The DP IV-inhibitor P32/98 is actively transported via the
PepT1 intestinal peptide transporter. The fast and active transport
of P32/98 through the intestinal mucosa is responsible for its fast
onset. The t.sub.max is a prerequisite for the efficient targeting
of dipetidylpeptidase IV (DP IV). Oral administration of P32/98
results in a maximum target inhibition 15 to 20 min and 30 to 40
min after ingestion in rats and men, respectively. Therefore, the
DP IV-inhibitor should be given 10-20 min prior to glucose or meal
intake.
[0036] In the first-human study with P32/98, pharmacodynamic
parameters like insulin concentration and GLP-1 concentration in
the plasma and blood glucose were investigated in 36 healthy male
volunteers. The oral dosing of P32/98 was in the following
concentrations: 7.5 mg, 15 mg, 30 mg, 60 mg, 120 mg and 240 mg. The
results of above pharmacodynamic parameters are summarized below in
Table 1.
[0037] The 36 healthy male subjects were divided into 3 individual
groups with each group containing 12 subjects. In each individual
group 9 subjects received active drug P32/98 and 3 received
placebo. The subjects receiving active drug were dosed twice, at
different periods and at different strengths. The strengths of the
P32/98 received within the groups were as follows: group I received
7.5 mg and 60 mg; group II received 15 mg and 120 mg; and group III
received 30 mg and 240 mg. The subjects in all groups who were
receiving placebo were given placebo at both dosing intervals.
[0038] A pre-study examination of the subjects was conducted within
3-14 days before their participation in the study. A second portion
of the study comprised an experimental phase and entailed six
single-dose treatments of ascending concentrations of P32/98,
(periods 1 to 6; Table 2) which concluded with a follow up
examination. Each subject participated in the pre-study and
experimental phase, which were separated by a washout phase of at
least 5 days. The follow-up examination was done at least 7 days
after the last dose of study drug. The study procedures of the six
periods were identical, except for the dose under
investigation.
[0039] Methods
[0040] Oral glucose tolerance test ("OGTT"): Subjects were required
to be in a fasting state for at least 12 hours and comply with a
carbohydrate-rich diet 3 days before each OGTT. At each glucose
tolerance test, subjects ingested 300 mL of a mono-/disaccharid
solution equivalent to 75 g glucose (Dextro.RTM. O.G.-T, Boehringer
Mannheim, FRG). Blood samples (1.2 mL into sodium fluoride tubes)
were taken immediately prior to glucose intake and at 30, 60, 90
and 120 min thereafter. Any glucose concentration above 126 mg/dl
(7.0 mmol/L) at 0 min and 120 min was considered to be in a
pathological glucose tolerance state. An extended OGTT was
performed on Day 1 of each dosing period. Subjects ingested 300 mL
of a mono-/disaccharid solution equivalent to 75 g glucose. Blood
samples (1.2 mL) were taken at the following intervals: 1) 5
minutes prior to glucose intake; 2) at 5, 15, 30, 45, 60, 75, 90,
120, 150 and 180 min after glucose intake; 3) 4, 12, and 24 and 48
hours after glucose intake. Additionally other pharmacodynamic
assessments that are well known in the art were taken.
[0041] Insulin: 4.7 ml blood was collected into 4.9 ml EDTA-tubes.
Samples were centrifuged (1500 g, 10 min) and stored frozen at
-70.degree. C. until laboratory analysis.
[0042] Glucose: 1.2 ml blood was collected into 1.2 ml sodium
fluoride tubes. Plasma samples were centrifuged at 1500 g for 10
min and stored frozen at -70.degree. C. until laboratory
analysis.
[0043] GLP-1: 2.7 ml blood was collected in EDTA tubes and placed
on ice or refrigerated, to which a dipeptidyl peptidase
IV-inhibitor was added. The inhibitor was prepared in advance by
researchers. Blood was collected in tubes and centrifuged
immediately at 1000 g for 10 min in refrigerated centrifuge or the
blood was placed in ice and centrifuged within 1 hour and aliquoted
into equal samples. Blood was stored in appropriate aliquots at
-70.degree. C. (to avoid multiple freezing/thawing cycles) until
laboratory analysis.
[0044] Results
[0045] Active GLP-1 concentrations A dose-dependent effect of
P32/98 compared to placebo was found. Overall individual
concentrations varied between 2-68 pmol/l. Pre-dose group means
were between 3.77.+-.2.62 pmol/l and 6.67.+-.9.43 pmol/l and
increased by up to 4.22 and 7.66 pmol/l following use of a placebo,
but by 11.6 pmol/l (15 mg) and 15.99 pmol/l (240 mg P32/98)
following use of the inhibitor. If the relative mean increase is
estimated from the absolute concentrations, active GLP-1
concentrations increased by approximately 200-300% after placebo
treatment, but by approximately 300-400% following P32/98
treatment. The absolute increase in medians after 15-240 mg P32/98
was 2-3-fold higher compared with placebo and the 7.5-mg dose (see
Table 1) and roughly indicated a dose-response relationship. An
increase above pre-dose values was present up to approximately 3-4
hours relative to the P32/98 dose.
[0046] Insulin concentrations showed an overall individual range of
values between 3.40 and 155.1 .mu.IU/ml. Mean (.+-.SD) pre-dose
concentrations varied between 7.96.+-.1.92 .mu.IU/ml (30 mg) and
11.93.+-.2.91 .mu.IU/ml (60 mg P32/98). Following the ingestion of
75 g of glucose at 10 min post-dose P32/98/placebo, mean insulin
concentrations increased by 30.12 .mu.IU/ml (120 mg P32/98) to
56.92 .mu.IU/ml (30-mg group) within 40-55 min. There was no
apparent difference between placebo and the P32/98 dosing groups
and, again, no evidence for a dose-dependent effect of P32/98.
Interestingly, the absolute increase in insulin concentration was
lowest in the two highest P32/98 dosing groups (see Table 1). The
insulin concentrations were elevated for 3-4 hours in all study
groups including placebo.
[0047] Glucose concentrations showed an overall range between 2.47
to 11.7 mmol/l in the fasted state, during OGGT or after meals
across all study subjects. Mean pre-dose concentrations between
4.55.+-.0.41 (15 mg) and 4.83.+-.0.30 mmol/l (7.5 mg P32/98)
closely matched each other and showed little variation. Mean
maximum concentrations were reached within 40-55 min post-dose,
i.e. within 30-45 min after the 75 g glucose dose. Absolute mean
concentrations were highest in the two placebo and 7.5 mg P32/98
dosing groups. The lowest absolute means were obtained from the 15
mg, 60 mg an d-240 mg dosing groups. The corresponding mean changes
ranged between 3.44 to 4.21 mmol/l and 1.71 to 3.41 mmol/l,
respectively, and closely matched the medians provided in Table 1.
Although no perfect dose-dependency was observed, these results
indicate a lower increase in glucose concentrations with increasing
doses from 15-240 mg of P32/98 compared with placebo.
1TABLE 1 Maximum Changes in Pharmacodynamic Parameters (0-12 h,
medians) Placebo 7.5 mg 15 mg 30 mg Placebo 60 mg 120 mg 240 mg
(1-3) P32/98 P32/98 P32/98 (4-6) P32/98 P32/98 P32/98 GLP-1, active
3.90 4.10 10.00 10.60 5.30 12.20 11.10 14.50 [pmol/l] 0:25 h 1:10 h
0:25 h 0:40 h 0:40 0:25 h 0:25 h 0:25 h insulin 46.29 41.86 29.67
59.84 42.90 43.35 28.63 33.36 [.mu.IU/ml] 0:55 h 0:55 h 0:55 h 0:40
h 0:40 h 0:40 h 0:40 h 0:40 h glucose 3.43 4.66 2.43 3.38 5.33 2.92
2.39 1.73 [mmol/l] 0:55 h 0:55 h 0:55 h 0:40 h 0:55 h 0:40 h 0:40 h
0:40 h
[0048]
2TABLE 2 Corrected C.sub.max and AUC of Glucose Concentrations 0-3
h After OGTT AUC.sub.0.fwdarw.180 min [mmol*min/l] C.sub.max [mmol]
Mean .+-. SD Estimate.sup.1 95% CI Mean .+-. SD Estimate 95% CI
Periods 1-3 Placebo 223.9 .+-. 143.3 4.16 .+-. 1.10 7.5 mg P32/98
299.7 .+-. 111.4 75.8 -48.1 - 199.7 4.94 .+-. 1.58 0.78 -0.40 -
1.96 15 mg P32/98 130.9 .+-. 125.2 -93.0 -216.9 - 30.9 2.92 .+-.
1.10 -1.24* -2.43 - -0.06 30 mg P32/98 116.1 .+-. 134.0 -107.7
-231.6 - 16.2 3.26 .+-. 1.07 -0.90 -2.08 - 0.28 Periods 4-6 Placebo
252.9 .+-. 103.3 4.91 .+-. 1.14 60 mg P32/98 151.8 .+-. 99.2 -101.1
-204.8 - 2.6 3.50 .+-. 1.66 -1.41* -2.66 - -0.17 120 mg P32/98
126.7 .+-. 147.3 -126-1* -229.8 - -22.4 3.09 .+-. 1.47 -1.82**
-3.07 - -0.58 240 mg P32/98 24.7 .+-. 66.6 -228.2*** -331.8 -
-124-5 1.99 .+-. 0.69 -2.92*** -4.16 - -1.68 .sup.1Results from
ANOVA comparison versus placebo *p < 0.05; **p < 0.01; ***p
< 0.001
[0049] Baseline-corrected mean peak (C.sub.max) glucose
concentrations exceeded 4.0 mmol/l in the two placebo and 7.5 mg
P32/98 dosing groups only. These values were also below 3.0 mmol/l
in the 15 mg and the 240 mg P32/98 treatment groups. The difference
compared to placebo treatment was statistically significant for the
15 mg, 60 mg, 120 mg and 240 mg P32/98 dosing groups, but not for
the 7.5 mg and the 30 mg dose groups. Mean baseline-corrected AUC
values were >200 mmol*min/l after placebo and 7.5 mg P32/98, but
clearly below 200 mmol*min/l following the 15 mg and 240 mg P32/98
doses. The reduction, in systemic glucose exposition from the OGTT
was statistically significant for the 15 mg, 60 mg, 120 mg and 240
mg P32/98 dosing groups, but not for the 7.5 mg and 30 mg dose
groups (see Table 2). The evaluation of baseline-corrected values
was very similar to those obtained from uncorrected data. Thus, the
data indicated a clearly lower glucose exposition after the OGTT in
P32/98 treated healthy subjects, which was an approximate, but not
perfect dose-dependent indication.
CONCLUSIONS
[0050] Results of this study allow the following pharmacodynamic
conclusions: Active GLP-1 increased by approximately 300-400%
following P32/98 treatment 10 min prior to OGTT, but no effect
discernible from placebo treatment was seen for the 7.5-mg dose
level (see FIGS. 1 and 2). Insulin concentrations appeared to be
decreased at doses of 120-240 mg following stimulation with 75 g
glucose. During the OGTT in healthy subjects, glucose
concentrations showed a significantly lower increase after P32/98
treatment (15-240 mg) compared with placebo, which was related to
the P32/98 dose.
Example 2
[0051] In the obese Zucker rat, P32/98 nutrient-dependent supports
initial insulin secretion. However, during a subchronic treatment,
P32/98 reduces the total daily insulin secretion. Compared to a
control glibenclamide, which increases insulin output by 27%,
P32/98 causes an economization of insulin by saving 45% compared to
the control.
[0052] Testing was undertaken to determine whether P32/98 is a
prime candidate to influence glucose tolerance in vivo by
increasing the circulating half-lifes of the incretins GIP and
GLP-1. Comparative studies were carried out with glibenclamide
(Maninil.RTM. Berlin-Chemie, Berlin, Germany) as reference
substance. Glibenclamide is one of the most effective drugs for
reducing blood glucose in Type 2 diabetic patients and one of the
most frequently prescribed sulphonylureas.
[0053] Male Zucker fa/fa rats, which exhibit abnormalities in
glucose metabolism and are a well established animal model for Type
2 diabetes, were investigated in the following way:
[0054] P32/98 and glibenclamide were given once daily before food
intake for a period of 21 days. The parameters monitored were
morning blood glucose and plasma insulin levels. In a day-night
profile, glycemia and insulinaemia were monitored from day 16 to
day 17. An OGTT was performed finally on day 21 to monitor blood
glucose and plasma insulin kinetics to assess changes in glucose
tolerance. Glibenclamide (DAB 1996; R011150/33372) was donated by
Berlin-Chemie (Berlin, Germany). Male Zucker (fa/fa) rats of the
body weight class of 300 g were purchased from Charles River
(Sulzfeld, Germany).
[0055] Methods Housing Conditions: Animals were kept single-housed
under conventional conditions with controlled temperature
(22.+-.2.degree. C.) on a {fraction (12/12)} hours light/dark cycle
(light on at 06:00 a.m.). Standard pellets (ssniff.RTM., Soest,
Germany) and tap water acidified with HCl were allowed ad
libitum.
[0056] Catheterization of Carotid Artery: After one week of
adaptation carotid catheters were implanted in the rats under
general anesthesia (injection of 0.25 ml/kg i.p. Rompun.RTM. [2%],
Bayer, Germany) and 0.5 ml/kg i.p. Velonarkon.RTM.
(Arzneimittelwerk Dresden, Germany). The animals were allowed to
recover for one week. The catheter was flushed with heparin-saline
(100 IU/ml) three times per week.
[0057] Repeated Dosing: 30 male non-diabetic Wistar and 30 male
diabetic Zucker rats were randomized to RP (Reference Product:
glibenclamide)-, TP-(Test Product: P32/98) and CO-(Control) groups
(N=10 per group). Thereafter, the non-diabetic Wistar rats were
treated orally once daily with RP (5 mg/kg b.w.) or TP (21.61 mg/kg
b.w.) and the diabetic Zucker rats were treated orally once daily
with RP (1 mg/kg b.w.) or TP (21.61 mg/kg b.w.) for 21 days at
05.00 p.m. (before regular food intake in the dark phase). The
controls were given 1% cellulose solution orally (5 ml/kg). Blood
samples were taken every morning at 07.30 a.m. from tail veins for
measurement of blood glucose and plasma insulin. The last blood
samples of this part of the program were taken at 07.30 a. m. on
the 15.sup.th day to measure blood glucose and plasma insulin. The
oral drug therapy was continued for one week. Recording the
day-night profile under the above therapy blood glucose (.DELTA.t=3
h) and plasma insulin (.DELTA.t=3-6 h) were monitored from day 16
(at 05.00 p.m. beginning) to day 17 (at 02.00 p.m. end).
[0058] OGTT: A final OGTT was performed on day 21 with blood
sampling from the tail vein. Blood samples from the tail vein were
taken at -12 h (the night before day 21), at 0 min (immediately
before the beginning of OGTT), at 10, 20, 30, 40, 50, 60, 80, 100
and 120 min. Blood samples were taken in 20 .mu.l glass capillaries
for blood glucose measurements and in Eppendorf tubes (100 .mu.l).
The latter were immediately centrifuged and the plasma fractions
were stored at -20.degree. C. for insulin analysis.
[0059] Blood glucose: Glucose levels were measured using the
glucose oxidase procedure (Super G Glukoseme.beta.gert; Dr. Muller
Gertebau, Freital, Germany).
[0060] Plasma insulin: Insulin concentrations were assayed by the
antibody RIA method (LINCO Research, Inc. St. Charles, Mo.,
USA).
[0061] Results
[0062] Day-night profile of glycemia (see FIG. 4A): The mean blood
glucose concentration in the CO-group on day 16 was 7.78.+-.0.83
mmol/l before drug application at 05.00 p.m. After oral placebo
ingestion and food intake in the dark phase glycemia increased to
maximum values of 12.18.+-.1.34 mmol/l at 11.00 p.m. Thereafter,
glycemia declined very slowly to the lowest values of 7.27.+-.0.61
mmol/l at 11. a.m., followed by an increase to 8.90.+-.0.92 mmol/l
at 02.00 p.m. next day. In the RP-group, a similar picture of
glycemia was seen. However, from a comparable mean value of
7.96.+-.1.13 mmol/l at 05.00 p.m. with respect to control animals
there was a stronger increase to 14.80.+-.1.46 mmol/l (11.00 p.m.)
and thereafter a decline to 7.66.+-.1.22 mmol/l (11.00 a.m.) and a
further slight reduction to 7.34.+-.0.77 mmol/l at 02.00 p.m. of
the next day, respectively. In the TP-group the Zucker rats had a
normal mean blood glucose value of 5.25.+-.0.16 mmol/l at 05.00
p.m. and the individual values were in the range from 4.34 to 6.07
mmol/l. Glycemia showed an increase of about 3 mmol/l to
8.34.+-.0.47 mmol/l at 11.00 p.m. This was followed by a permanent
decline to basal values which were reached at 08.00 a.m.
(5.64.+-.0.23) and which were maintained at 11.00 a.m.
(5.33.+-.0.14 mmol/l) and 02.00 p.m. next day (5.51.+-.0.19
mmol/l), respectively.
[0063] Day-night profile of insulinemia: (see FIG. 4B): The CO- and
RP-Zucker rats were strongly hyperinsulinemic. Insulin showed a
variability in mean values at 05.00 p.m. in the CO-group (47.018.7
ng/ml), 08.00 p.m. (45.5.+-.7.7 ng/ml), 05.00 a.m. (54.2.+-.5.7
ng/ml) and 02.00 p.m. next day (61.0.+-.10.2 ng/ml; NS) which
showed no relation to the excursions of blood glucose. In RP-group
in the dark phase from 06.00 p.m. to 06.00 a.m. there was a
significant increase in plasma insulin values with a maximum at
5.00 a.m. This parameter increased from strongly hyperinsulinemic
values of 50.0.+-.8.2 ng/ml (05.00 p.m.) via 57.3.+-.8.2 ng/ml
(08.00 p.m.) to 76.3.+-.8.6 ng/ml (05.00 a.m.; p<0.01 vs.
initial value), which was followed by a decline to. 58.3.+-.7.3
ng/ml (02.00 p.m. the next day). In this RP-group insulin was
strongly phase shifted in relation to the blood glucose excursions.
In the TP-group, the Zucker rats were also hyperinsulinemic. Plasma
insulin at 05.00 p.m. was significantly lower than in the RP
(p<0.05 vs. RP). Parallel to blood glucose increases (FIG.
IV/3A) there was an increase in plasma insulin at 08.00 p.m.
(41.9.+-.8.5 ng/ml). The maximum insulin value was measured at
05.00 a.m. (57.1.+-.8.6 ng/ml; p<0.01 vs. initial values). The
concentration of plasma insulin was lowered reaching basal
concentration (24.3.+-.3.7 ng/ml) at ca. 2.00 p.m. the next day
which was significantly lower than in CO or RP groups (p<0.01
vs. CO or TP).
[0064] OGTT after 21 days treatment, blood glucose curves (See FIG.
5A): The last drug application at 05.00 p.m. and overnight fasting
on day 21 were followed by a significant decline in glycemia in the
CO-group from 8.68.+-.1.26 mmol/l (05.00 p.m.) to 5.08.+-.0.24
mmol/l (p<0.05), in the RP group from 8.81.+-.1.21 mmol/l to
4.91.+-.0.37 mmol/l (p<0.01) and in the TP-group from
5.75.+-.0.23 mmol/l to 4.88.+-.0.13 mmol/l (p<0.01). For this
reason oral glucose loads were performed from a comparable basal
glucose concentration level in all three experimental groups found
in the morning (07.30 a. m.).
[0065] In the CO-group glycemia increased after oral glucose
application to peak values of 14.64.+-.1.42 mmol/l within 40 min.
Later there was a slight, significant decline to 9.75.+-.0.46
mmol/l at the end of the test (120 min). In the RP-group, there was
a steep increase to higher blood glucose values of 16.33.+-.0.98
and 16.24.+-.1.09 mmol/l at 50 min and 80 min, respectively. The
high glucose concentrations were maintained until the end of study
at 120 min (100 min: 15.13.+-.0.76 mmol/l, 120 min: 14.81.+-.0.66
mmol/l; NS from the former peak values). In the TP-group, similar
properties of the mean blood glucose curve as in the CO-group were
found. Glycemia increased to 14.54.+-.0.65 mmol/l at 50 min and
declined significantly to a value of 10.67.+-.0.62 mmol/l (120 min;
NS from CO).
[0066] The glucose area under the curve (G-AUC.sub.0-120 min) in
the CO- and TP-groups were 823.+-.41 and 895.+-.50
mmol.multidot.min/l, respectively (NS). In the RP-group this
parameter was determined as 1096.+-.76 mmol.multidot.min/l and that
value was significantly higher than in CO- (p<0.01) or TP-groups
(p<0.05).
[0067] OGTT after 21 days treatment, plasma insulin (See FIG. 5B):
Overnight fasting in the Zucker rats led to reduced plasma insulin
concentrations in the CO-animals (14.6.+-.3.7 ng/ml), in the
RP-group to 11.8.+-.1.5 ng/ml, and in the TP-group to 9.3.+-.1.5
ng/ml, respectively. The differences between experimental groups
were not significant. After a glucose stimulus, plasma insulin
remained mostly unchanged in the CO-, RP- and TP-groups. Slightly
higher values were found at 120 min in the CO-group only, amounting
to 21.3.+-.3.0 ng/ml, which was significantly higher than in the
TP-group (p<0.05).
[0068] The I-AUC.sub.0-120 ml was generally low. In the TP-group
this parameter was lower than in the CO- or RP-groups (NS).
SUMMARY
[0069] Morning blood glucose: The placebo treated controls were
hyperglycemic (about 7.5 mmol/l). The mean concentration was
unchanged during the study. RP therapy increased blood glucose by
about 1.5 mmol/l within two days. Glycemia remained in the higher
range. TP-medication reduced blood glucose to a normal value within
5 days. Blood glucose remained in the normal range up to the end of
the study.
[0070] Plasma insulin: The control Zucker rats were
hyperinsulinemic and showed some further insulin increase during
the 14 days of observation. The RP-treated Zucker rats showed an
insulin increase to significantly higher concentrations than in
control animals. The TP application did slightly decrease insulin
concentration for 14 days in comparison to the control animals.
[0071] OGTT after 21 days treatment, blood glucose: Overnight
fasting reduced blood glucose to normal values in the experimental
groups. The placebo-treated animals showed about a 9 mmol/l blood
glucose increase within 40 min after the glucose load and a slight
decline thereafter. RP-treated Zucker rats showed a about 11 mmol/l
blood glucose increase after the glucose load with no decline
during the test. The mean blood glucose curve of the TP-treated
animals was not different from that of the controls. The
RP-treatment increased the G-AUC, the TP-medication did not
increase G-AUC in comparison to the placebo application.
[0072] OGTT after 21 days treatment, plasma insulin: The control
Zucker rats had the highest fasting insulin of the three
experimental groups of about 15 ng/ml. After the glucose load,
insulin increased significantly only at the end of the test (120
min). The RP-treated rats had some lower fasting insulin of 12.5
ng/ml at the beginning of the OGTT and an earlier increase at 40
min with no decline at the end of the test. The TP-treated rats had
the lowest fasting insulin of .about.9 ng/ml at the beginning of
the OGTT, an early modest increase at 20 min in relation to the
blood glucose rising and lowered concentrations between 40 min and
100 min. The I-AUC was slightly lower in the TP-treated rats.
CONCLUSION
[0073] The DP IV inhibitor P32/98 (TP), given once daily,
normalized morning blood glucose, reduced hyperinsulinemia, held
blood glucose in the day-night profile below the (for diabetic
patients) critical 8.3 mmol/l. The metabolic benefit was retained a
limited time after cessation of P32/98 medication.
* * * * *